You've always been someone who could handle things. Pressure at work, family demands, the constant logistics of daily life. You managed. Maybe you weren't perfectly calm, but you were functional. You were yourself.

And then something changed. Maybe it was anxiety that showed up uninvited, a tightness in your chest that wasn't there before, a sense of dread when you wake up, worry that spirals in ways it never used to. Maybe it was rage: a white-hot anger at your partner, your kids, or the person who cut you off in traffic, an intensity that feels completely disproportionate to the situation and completely unlike you. Maybe you cried at a commercial, or at nothing at all, and thought: what is happening to me?

What's happening has a name, and it has a mechanism. During perimenopause, the hormones that regulate your neurotransmitters, the brain chemicals that govern mood, emotional reactivity, and anxiety, are in flux. This isn't a personality change. It's a neurochemical one.

The Hormonal Connection to Mood

Estrogen is far more than a reproductive hormone. It is one of the most powerful modulators of brain chemistry, directly influencing the production, receptor sensitivity, and breakdown of three neurotransmitters that are central to mood regulation:

  • Serotonin: Often described as the "well-being" neurotransmitter. Estrogen promotes serotonin synthesis and slows its reuptake, effectively keeping more serotonin active in your brain. When estrogen fluctuates unpredictably, as it does during perimenopause, sometimes swinging higher than your reproductive peak before dropping sharply, serotonin levels become unstable. This can manifest as low mood, irritability, and increased emotional sensitivity.
  • GABA (gamma-aminobutyric acid): Your brain's primary inhibitory neurotransmitter, the one that calms neural activity and reduces anxiety. Estrogen supports GABA receptor function. When estrogen levels drop, GABA signaling weakens, and the nervous system becomes less able to dampen its own alarm responses. The subjective experience: you feel more anxious, more on edge, more easily overwhelmed.
  • Dopamine: The neurotransmitter associated with motivation, focus, and reward. Estrogen supports dopamine production and receptor sensitivity. Fluctuating estrogen can reduce dopamine activity, contributing to a flattened sense of motivation, difficulty experiencing pleasure in things you used to enjoy, and trouble concentrating.

The critical point is that during perimenopause, estrogen doesn't decline in a smooth, predictable line. It fluctuates erratically, sometimes surging to levels higher than you experienced during your reproductive years before dropping steeply, as described by the Cleveland Clinic. Each swing creates a corresponding disruption in neurotransmitter activity. It's the instability, not the level itself, that drives many of the mood symptoms.

Progesterone's Role: The Natural Anxiolytic

While estrogen's fluctuations tend to get the most attention, progesterone's decline is equally important for understanding perimenopause-related mood changes, particularly anxiety.

Progesterone has a direct calming effect on the brain. It is metabolized into allopregnanolone, a neurosteroid that enhances GABA-A receptor activity, the same receptor system targeted by benzodiazepines and alcohol. In essence, progesterone acts as your body's built-in anti-anxiety medication.

Progesterone is often the first hormone to decline in perimenopause, as anovulatory cycles (cycles where you don't ovulate) become more frequent. Without ovulation, no corpus luteum forms, and without the corpus luteum, progesterone production drops significantly. The result: less of the neurosteroid that was helping keep your nervous system calm.

This is one reason why anxiety can be one of the earliest mood symptoms in perimenopause, sometimes appearing years before other symptoms become noticeable.

The Rage Phenomenon

Of all the mood changes women describe during perimenopause, rage may be the most unsettling because it feels so fundamentally out of character.

Women who have spent decades as the calm one, the patient one, the person who smooths things over, describe a sudden capacity for anger that is startling in its intensity. Slamming doors. Screaming at their children. Fantasizing about walking out of their own lives. The anger often feels disproportionate to its trigger, which adds shame on top of the anger itself.

There are several layers to what's happening here. On a purely neurochemical level, declining estrogen reduces serotonin activity (which helps regulate emotional reactivity) and weakens GABA-mediated calming, while declining progesterone removes another layer of neural inhibition. The result is a nervous system that is more reactive and less buffered.

But some researchers have proposed an additional dimension. Estrogen, through its effects on serotonin and oxytocin systems, may have served as a neurochemical buffer that facilitated agreeableness, empathy-driven compliance, and what is sometimes described as "tending and befriending." As this buffer diminishes, some women experience not a pathological rage but an unfiltered clarity about what they've been tolerating: unequal domestic labor, boundary violations, relationships that take more than they give. The anger, in this framing, isn't irrational. It's a feeling that was always there but was neurochemically dampened.

This doesn't mean all perimenopause-related anger is a revelation about your life circumstances. Hormonal irritability is real and can make you reactive to things that genuinely don't warrant it. But the experience many women describe, a sudden unwillingness to accommodate, to smooth things over, to put everyone else first, may reflect both hormonal change and a shift in what you're willing to accept.

Anxiety vs. Hormonal Shifts: How to Tell the Difference

One of the more confusing aspects of perimenopause-related mood changes is that they can look identical to psychiatric conditions. New-onset anxiety during perimenopause can present exactly like generalized anxiety disorder. Mood instability can resemble bipolar spectrum conditions. Depression can meet every diagnostic criterion for major depressive disorder.

There are some features that suggest a hormonal contribution:

  • Timing: Symptoms that worsen in a pattern related to your menstrual cycle (particularly in the luteal phase, the two weeks before your period) or that emerged during a time when your cycle was becoming irregular suggest a hormonal component.
  • Age of onset: New anxiety or mood instability appearing in your late 30s or 40s, without a prior history, is worth evaluating through a hormonal lens, particularly if it's accompanied by other perimenopause symptoms like sleep disruption, hot flashes, or cycle changes.
  • Response to treatment: Some women with hormonally-driven mood symptoms respond better to hormone therapy than to SSRIs. Others respond well to SSRIs. This distinction can itself be informative, though both approaches can be appropriate depending on the situation.
  • Other perimenopause symptoms: If your anxiety or mood changes arrived alongside night sweats, irregular periods, sleep disruption, or other perimenopause symptoms, the likelihood of a hormonal driver increases.

In practice, the distinction is often less binary than "hormonal" vs. "psychiatric." Hormonal changes can trigger a depressive episode in someone with a vulnerability to depression, or unmask anxiety that was previously subclinical. Both the hormonal and psychological dimensions may need to be addressed.

The Misdiagnosis Problem

Many women in perimenopause are prescribed SSRIs or SNRIs for mood symptoms without anyone evaluating whether hormonal changes might be a contributing factor. This happens frequently: a woman in her early 40s presents to her primary care provider with new-onset anxiety, sleep disruption, and irritability. The most readily available diagnosis is anxiety disorder or depression, and the most readily available treatment is an antidepressant.

SSRIs and SNRIs can be genuinely helpful for perimenopause-related mood symptoms because they increase serotonin activity, partially compensating for estrogen's declining influence on that system. They are a legitimate treatment option, not the wrong answer.

But they may be an incomplete answer. If the root driver is hormonal instability, an SSRI may blunt the worst of the mood symptoms without addressing the full picture. Some women find that adding hormone therapy to their treatment regimen provides improvement that the antidepressant alone did not. Others find that hormone therapy alone resolves their mood symptoms without the need for an antidepressant.

The problem isn't that SSRIs are prescribed. It's that the hormonal context is often never explored, leaving women without the full range of treatment options.

Depression in Perimenopause

The perimenopause window carries a two- to four-fold increased risk of a depressive episode, even in women with no prior history of depression. This is well-established in the research, including findings highlighted by the North American Menopause Society, and appears to be driven by the hormonal instability itself rather than by life circumstances, though life circumstances certainly contribute.

Women who are at particularly elevated risk include those with a history of:

  • Premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD): If your mood was always sensitive to hormonal fluctuations across your menstrual cycle, perimenopause's more dramatic fluctuations can amplify that vulnerability.
  • Postpartum depression: The postpartum period shares features with perimenopause, as both involve rapid hormonal shifts. A history of postpartum depression suggests sensitivity to these transitions.
  • Prior depressive episodes: A history of depression at any point increases the risk of recurrence during perimenopause.

If you've experienced depression before and are entering perimenopause, it's worth proactively discussing this with your provider. Early intervention can prevent a full depressive episode from developing.

ADHD Unmasking

One of the more recently discussed phenomena in perimenopause is the apparent emergence, or worsening, of ADHD symptoms. Women who were never diagnosed with ADHD, or who managed it effectively for decades, find themselves suddenly struggling with executive function, time management, focus, and working memory in ways that feel new and disabling.

This has a hormonal basis. Estrogen supports the dopamine and norepinephrine systems, which are the neurotransmitter systems most involved in attention, executive function, and impulse control, which are the same systems that are underactive in ADHD. When estrogen levels were stable and adequate, these systems may have been functioning well enough that ADHD traits remained subclinical or compensated. As estrogen fluctuates and declines, those compensatory mechanisms weaken.

If you've always been someone who needed lists, struggled with time blindness, or found yourself starting projects without finishing them, but managed to stay on top of things, perimenopause can remove the margin that allowed you to compensate. The ADHD was likely always present, but estrogen was providing enough dopaminergic support to keep it below the threshold of impairment.

If this resonates, it's worth pursuing an ADHD evaluation. Treatment options include both hormonal approaches (estrogen can improve attention and executive function for some women) and traditional ADHD medications, which may be more effective when hormonal factors are also addressed.

What Helps

Hormone therapy (HT)

For mood symptoms that are primarily driven by hormonal instability, hormone therapy can be remarkably effective. Estrogen stabilizes the serotonin, GABA, and dopamine systems that have been disrupted. Progesterone, particularly micronized progesterone, adds its own anxiolytic and sleep-promoting benefits.

HT tends to be most effective for mood symptoms when started during perimenopause rather than years after menopause. This aligns with the "window of opportunity" hypothesis, which suggests that the brain is most responsive to hormonal support when the changes are still actively occurring. If mood is your primary concern, this is worth discussing with a menopause-informed provider sooner rather than later.

Therapy, particularly CBT

Cognitive behavioral therapy (CBT) has strong evidence for treating anxiety and depression during perimenopause, both on its own and in combination with other approaches. CBT helps you identify and restructure thought patterns that amplify distress, such as catastrophizing, rumination, and the "I'm falling apart" narrative that often accompanies hormonal mood changes.

CBT doesn't address the hormonal component directly, but it can significantly reduce the emotional suffering that the hormonal changes provoke. It's also a valuable tool for developing coping strategies that will serve you throughout and beyond the menopausal transition.

Exercise, especially strength training

Regular physical activity is one of the most consistently supported interventions for mood during perimenopause, and strength training (resistance training) appears to offer particular benefits. Strength training increases BDNF (brain-derived neurotrophic factor), which supports neuroplasticity and has antidepressant effects. It also improves insulin sensitivity, supports bone density, and can improve sleep quality, addressing several perimenopause concerns simultaneously.

Aerobic exercise also benefits mood through endorphin release, serotonin synthesis, and cortisol regulation. A combination of both aerobic and resistance training, at least 3 to 4 times per week, appears to produce the best outcomes for mood and overall well-being during perimenopause.

Sleep optimization

Because sleep disruption independently worsens mood, anxiety, and cognitive function, improving sleep quality can have an outsized positive effect on emotional well-being. Many women find that their mood symptoms improve significantly when their sleep improves, even before other interventions are added. Addressing sleep should be considered a core part of any mood management strategy during perimenopause.

SSRIs and SNRIs

When mood symptoms are severe, persistent, or not adequately addressed by other approaches, SSRIs and SNRIs remain effective and appropriate non-hormonal treatment options. They can be used alone or in combination with hormone therapy. For some women, the combination of an SSRI plus HT produces better results than either alone.

The Bottom Line

The mood changes of perimenopause are real, physiological, and well-documented. They arise from the interaction between shifting reproductive hormones and the neurotransmitter systems that regulate how you feel, how you cope, and how you respond to the world around you.

They are not a sign of weakness. They are not "hysteria," a word with roots in the very dismissal of women's hormonal experiences. And they are not something you need to endure in silence or push through with more yoga and positive thinking.

Effective treatment exists. It may involve hormone therapy, therapy, medication, lifestyle changes, or some combination. The right approach depends on what's driving your specific symptoms, your medical history, and your preferences. What matters most is that you have the information to advocate for yourself and the confidence to know that what you're experiencing deserves to be taken seriously.

Because it does.